Psychedelic and ketamine research trials in the United Kingdom
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
34 registered studies are counted in the United Kingdom. By compound: 13 psilocybin, 1 MDMA, 2 LSD, 4 DMT, 2 5-MeO-DMT, 11 ketamine and 2 ibogaine. By registry status: 2 recruiting, 1 active, not recruiting, 24 completed, 2 terminated and 5 status not reported. By phase: 2 early phase 1, 16 phase 1, 4 phase 2, 2 phase 4, 8 not applicable and 2 not reported. Reported start years run from 2008 (earliest) to 2025 (latest). Studies are linked to 20 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
2 of the 34 counted studies are listed in the registry as recruiting (2) or not yet recruiting (0), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm | NCT06798636 | Recruiting | Early Phase 1 | 2025-10-01 | Imperial College London, London |
| Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs | NCT06815653 | Recruiting | Phase 1 | 2025-03-01 | University College, London, London |
At a glance
- 34 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 13 |
| MDMA | 1 |
| LSD | 2 |
| DMT | 4 |
| 5-MeO-DMT | 2 |
| Ketamine | 11 |
| Ibogaine | 2 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 2 | 6% |
| Active, not recruiting | 1 | 3% |
| Completed | 24 | 71% |
| Terminated | 2 | 6% |
| Status not reported | 5 | 15% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 2 | 6% |
| Phase 1 | 16 | 47% |
| Phase 2 | 4 | 12% |
| Phase 4 | 2 | 6% |
| Not applicable | 8 | 24% |
| Not reported | 2 | 6% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 7 |
| 2020 to 2023 | 17 |
| 2015 to 2019 | 5 |
| 2010 to 2014 | 3 |
| Before 2010 | 2 |
All counted studies
All 34 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm | NCT06798636 | Recruiting | Early Phase 1 | 2025-10-01 | Imperial College London, London |
| A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers | NCT07050368 | Completed | Phase 1 | 2025-07-28 | MycoMedica Life Sciences PBC, London |
| Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs | NCT06815653 | Recruiting | Phase 1 | 2025-03-01 | University College, London, London |
| Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects | NCT06511947 | Terminated | Phase 1 | 2024-08-01 | GH Research Ireland Limited, London |
| Multiple Ascending Dose Noribogaine PK/PD in Healthy Volunteers | NCT06480981 | Completed | Phase 1 | 2024-06-20 | DemeRx NB, London |
| (GluEsk) Glutamate and Esketamine | NCT06432322 | Completed | Not applicable | 2024-06-14 | University of Oxford, Oxford |
| Psilocybin in Functional Neurological Disorder | NCT05723276 | Completed | Not applicable | 2024-02-14 | King's College London, London |
| Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans | NCT05876481 | Status not reported | Phase 2 | 2023-06-01 | Combat Stress, Leatherhead |
| IM and IV SPL026 Drug Product in Healthy Participants | NCT05644093 | Completed | Phase 1 | 2023-01-03 | Small Pharma Ltd, London |
| SPL026 With or Without SSRIs in Participants With MDD | NCT05553691 | Completed | Phase 1 | 2022-12-13 | Small Pharma Ltd, Manchester |
| Psilocybin in Adults With and Without Autism Spectrum Disorder | NCT05651126 | Completed | Not applicable | 2022-12-12 | King's College London, London |
| PsilOCD: A Pharmacological-Challenge Feasibility Study | NCT06258031 | Completed | Phase 1 | 2022-10-28 | Imperial College London, London |
| Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action | NCT05548075 | Status not reported | Not reported | 2022-08-15 | Imperial College London, London |
| Glutamate Emotion Memory Study | NCT05809609 | Status not reported | Not applicable | 2022-07-01 | University of Oxford, Oxford |
| Synaptic Imaging and Network Activity in Treatment Resistant Depression | NCT05870501 | Completed | Not applicable | 2021-10-20 | King's College London, London |
| Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine | NCT04977674 | Completed | Early Phase 1 | 2021-09-27 | King's College London, London |
| Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects | NCT05032833 | Completed | Phase 1 | 2021-09-22 | Beckley Psytech Limited, London |
| Reward Emotion Learning and Ketamine Study | NCT04850911 | Status not reported | Not applicable | 2021-08-25 | University of Oxford, Oxford |
| Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA) | NCT04905121 | Terminated | Phase 1 | 2021-08-11 | Beckley Psytech Limited, London |
| Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin | NCT07164755 | Active, not recruiting | Not reported | 2021-06-21 | King's College London, London |
| Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study | NCT04505189 | Completed | Phase 1 | 2021-05-28 | Imperial College London, London |
| A Study of Oral Ibogaine in Opioid Withdrawal | NCT05029401 | Completed | Phase 1 | 2021-04-01 | atai Therapeutics, Inc., Manchester |
| SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients | NCT04673383 | Completed | Phase 1 | 2021-02-04 | Small Pharma Ltd, Liverpool |
| Psilocybin in Depression Resistant to Standard Treatments | NCT04959253 | Completed | Phase 2 | 2020-09-01 | King's College London, London |
| Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms | NCT03429075 | Completed | Phase 2 | 2019-01-07 | Imperial College London, London |
| Bristol Imperial MDMA in Alcoholism Study | NCT04158778 | Status not reported | Phase 1 | 2018-04-18 | Imperial College London, Bristol |
| Ketamine for Reduction of Alcoholic Relapse | NCT02649231 | Completed | Phase 2 | 2016-10-01 | University College, London, Exeter |
| A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers | NCT05674669 | Completed | Phase 1 | 2015-10-20 | Eleusis Therapeutics, London |
| A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years | NCT04421105 | Completed | Phase 1 | 2015-06-29 | Eleusis Therapeutics, London |
| Ketamine's Actions on Rumination Mechanisms as an Antidepressant | NCT04656886 | Completed | Not applicable | 2014-09-01 | King's College London, London |
| The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy | NCT01306760 | Completed | Phase 4 | 2011-03-01 | University of Aberdeen, Aberdeen |
| Effects of Ketamine and Risperidone on Cognition | NCT01140620 | Completed | Phase 4 | 2010-06-01 | University of Manchester, London |
| Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects | NCT01046630 | Completed | Phase 1 | 2009-12-01 | AstraZeneca, Manchester |
| Neurophysiology and Pharmacology of Cough Reflex Hypersensitivity | NCT00858624 | Completed | Not applicable | 2008-02-01 | University of Manchester, Manchester |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ketamine | Ibogaine
Institution hubs in this country
Institutions in this country with at least 3 counted studies. The number is that institution's own count of studies, which can include studies not shown above if the registry lists them under another country.
- King's College London: 7 studies
- Imperial College London: 5 studies
- University of Oxford: 3 studies
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
Other country hubs
United States | Canada | Switzerland | France | Israel | Brazil | China | Netherlands | Australia | Austria | Germany | Spain | Sweden | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Czech Republic | Denmark | Finland